, Tracking Stock Market Picks
Enter Symbol:
Rating: PACB
Buy $18

Pacific Biosciences of California (NASDAQ: PACB) rated to Buy with price target $18 by Cantor Fitzgerald

Monday,  Jan 4, 2016  10:25 AM ET by Lynn Gilbert

Cantor Fitzgerald rated Pacific Biosciences
of California (NASDAQ: PACB) to Buy with price target $18.

Pacific Biosciences of California is development-stage company. The Company develops, manufactures and markets an integrated platform for genetic analysis. The Company has developed a technology to study the synthesis and regulation of deoxyribonucleic acid (DNA). Combining advances in nanofabrication, biochemistry, molecular biology, surface chemistry and optics, the Company created a technology platform using its single molecule, real-time (SMRT) technology. Its SMRT technology uses the natural processing power of enzymes, combined with designed reagents and detection systems, to record individual biochemical events as they occur. The Company?s initial focus is on the DNA sequencing market where it has developed and introduced a third-generation sequencing platform using its SMRT technology, the PacBio RS.

Cantor U.S. Equity Research provides timely and insightful opinions on select stocks. We look at key drivers of the stock price, including company and industry fundamentals, capital markets influences and overall economic trends to provide critical and in-depth analysis. Our focus is on small and mid-cap companies in the following sectors: * Marine Transportation * Life Sciences * Clean Technology & Energy Efficiency * Real Estate * Communications Technology * Internet * Enterprise Software

RSS Feed | |  Facebook |  Twitter |  Google Plus
Home | Terms of Use | Advertise | FAQ | Support Page | Contact Us | About Us | Privacy Policy